8-K/A: Nowtransit Inc. Completes Reverse Merger with Best Labs, Inc., Shifting Focus to Health and Wellness Products

Nowtransit Inc. has completed a reverse merger with Best Labs, Inc., acquiring a portfolio of health and wellness products and changing its business focus.

Summary

• Nowtransit Inc., formerly a shell company, completed a reverse merger with Best Labs, Inc. on March 10, 2023.
• As a result of the merger, Best Labs became a wholly-owned subsidiary of Nowtransit.
• Nowtransit issued 34,371,100 shares of its common stock to Best Labs shareholders, representing approximately 85.39% of the company's outstanding shares post-merger.
• The company's business focus has shifted from online delivery to marketing and selling clinically-tested health and wellness products, including mouth sprays, nasal sprays, and brain support supplements.
• The company is targeting markets such as dementia, ADHD, long COVID, and general energy, among others.
• Nowtransit is leveraging a patent-pending Methylene Blue technology in some of its products.
• The company's financial statements now reflect the historical financials of Best Labs, with adjustments for Nowtransit's equity.
• For the year ended December 31, 2022, Best Labs had a net loss of $170,450 on revenue of $69,343.
• As of December 31, 2022, Best Labs had total assets of $31,608, consisting of cash, accounts receivable, and inventory.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a promising product line and market strategy, it faces significant financial challenges, including a history of losses, a going concern warning, and the need for additional capital. The penny stock status and limited trading volume also raise concerns.

Positives

• The company has a diverse product line targeting multiple health and wellness markets.
• The company has a patent-pending technology for Methylene Blue products.
• The company has established a medical advisory team to support product development and marketing.
• The company has a sales plan that includes online platforms and potential international distribution.
• The company has a supply chain manager, Ageless Holdings LLC, ensuring GMP-compliant production.

Negatives

• The company has a history of losses and a net capital deficiency.
• The company has minimal assets and limited operating history.
• The company is dependent on related party funding.
• The company's stock is traded on the OTC Pink Market and is considered a penny stock, which may limit liquidity.
• The company has no current commitments for additional funding.
• The company has a limited number of shareholders and trading volume is sporadic.
• The company has a going concern warning from its auditors.

Risks

• The company may need to raise additional capital in the future, which could dilute current investors.
• The company's stock price may be volatile due to factors beyond its control.
• The company may be unable to obtain necessary financing if and when required.
• The company faces competition from various supplement manufacturers and biotechnology firms.
• The company's products are subject to FDA and FTC regulations, which could lead to compliance issues.
• The company's reliance on a single supply chain manager, Ageless Holdings LLC, poses a risk.
• The company's stock is subject to penny stock rules, which may limit broker-dealer activity and liquidity.
• The company is a voluntary filer with the SEC, which may impact its ability to maintain current public information.

Future Outlook

The company plans to focus on gaining traction for its mental health and general wellness products, leveraging its patent-pending Methylene Blue technology and expanding its sales channels. The company believes it is well-positioned to capitalize on multiple market opportunities with adequate capital infusion.

Management Comments

• As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings.
• We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities.

Industry Context

The announcement reflects a growing trend in the health and wellness industry towards natural and alternative therapies, particularly those focused on mitochondrial health and cognitive function. The company is entering a competitive market with established players in both the supplement and biotechnology sectors.

Comparison to Industry Standards

• The company's focus on Methylene Blue supplements places it in competition with companies like Prohealth Longevity, Troscriptions, and Mercola Health Resources.
• In the broader mitochondrial health market, the company competes with Elysium Health, Tru Niagen (Chroma Dex), and Mitobridge (Astellas Pharma).
• Biotechnology firms like Stealth Bio Therapeutics, Meuronol, and Retrotope also represent competition in the area of mitochondrial health and neurodegenerative diseases.
• The company's financial results, with a net loss of $170,450 on revenue of $69,343 for 2022, are not uncommon for early-stage companies in the health and wellness sector, but it will need to demonstrate significant growth to achieve profitability.
• The company's reliance on online sales channels is consistent with many direct-to-consumer supplement brands, but it will need to expand its distribution to compete with larger players.

Management Changes

Related Party Transactions

• The company has received loans from related parties, including its CEO, to cover operating expenses.
• The company purchased inventory from Ageless Holdings, LLC, an entity owned and controlled by the company's CEO.
• The company issued shares of common stock to related parties for services.
• Loans from related parties were forgiven and considered a capital transaction.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances.
• Employees are not currently impacted as the company has no employees.
• Customers may benefit from the company's health and wellness products.
• Suppliers may benefit from the company's product sales.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to market and sell its products through online sales and in various other distribution channels.
• The company plans to file the US patent application by year's end and the PCT application next March.
• The company is revising its online platform to better capitalize on SEO and Google ads.
• The company is moving forward in establishing international distribution opportunities.

Key Dates

Keywords

Methylene Blue, Dietary Supplements, Reverse Merger, Health and Wellness, Mitochondrial Health, OTC Pink Market, Penny Stock, NeuroPro Plus, ADHD 365, Best Labs, Nowtransit, Brain Health, Nasal Spray, Mouth Spray